Why the study?
Does oral-mucosal administration of murine interferon-alpha enhance immune response and suppress vaccinia virus infection in mice?
Does oral-mucosal administration of murine interferon-alpha enhance immune response and suppress vaccinia virus infection in mice?
Oral-mucosal administration of murine interferon-alpha potentiates cellular and humoral immune responses and suppresses vaccinia virus infection in mice.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in mice; leaves open translation of oral-mucosal IFN-alpha to human antiviral immunity.
We studied the effects of oral-mucosal administration of murine interferon-alpha (Mu-IFN-alpha) on immune responses and infection with vaccinia virus (VV) in mice. When Mu-IFN-alpha was administered to sheep red blood cell (SRBC)-sensitized mice for 4 or 5 days, Mu-IFN-alpha significantly enhanced delayed-type hypersensitivity (DTH) and antibody production, with maximum enhancement of each at 1 IU/body. To investigate the antiviral effect of oral-mucosal Mu-IFN-alpha, mice were infected with VV, and Mu-IFN-alpha was administered for 15 days. Pocks were observed in the tail skin of infected mice, and Mu-IFN-alpha at doses of 1, 10, and 100 IU/body significantly suppressed pock formation. Also, VV-specific cytotoxic T cells (CTL) were observed in the spleen from the same mice at 7 days after infection, and Mu-IFN-alpha enhanced CTL activity at doses above 1 IU/body. These results suggest that the oral-mucosal Mu-IFN-alpha may have potentiating effects on cellular and humoral immune responses, which may contribute to its effects against VV.
No takes yet. Share an insight, caveat, or question.
NAGAO et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: